RxDoctor Payments Data

Sanjana Iddyadinesh, DO

Family Medicine · Greenville, SCNPI 1548641871

Payments from drug & device makers

$3,535in general payments, 2019–2025

Across 192 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$534
  • AstraZeneca$530
  • AbbVie$334
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$317
  • Novo Nordisk$221
  • Novartis$180
  • plus $1K from 32 others

What the payments were for

  • Food & beverage$3,535100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,535 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$46,031
Medicare patients
161
Services billed
582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin36$42,773
EliquisApixaban29$37,142
OzempicSemaglutide24$31,952
FarxigaDapagliflozin Propanediol15$21,129
MyrbetriqMirabegron23$18,323
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$18,155
XareltoRivaroxaban11$13,535
JanuviaSitagliptin Phosphate12$10,783
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$9,515
Albuterol Sulfate HfaAlbuterol Sulfate75$2,477
Atorvastatin Calcium188$1,353
SynthroidLevothyroxine Sodium15$1,238
Omeprazole87$1,216
Wixela InhubFluticasone Propion/Salmeterol16$1,094
Sucralfate12$1,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$534$42,77336 claims
PfizerEliquis$95$37,14229 claims
Novo NordiskOzempic$221$31,95224 claims
GSKTrelegy Ellipta, Anoro Ellipta$55$27,67142 claims
AstraZenecaFarxiga$530$21,12915 claims
Astellas Pharma US IncMyrbetriq$48$18,32323 claims
MerckJanuvia$98$10,78312 claims
AbbVieSynthroid$334$1,23815 claims
Lilly USA, LLCHumulin 70-30$121$86311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →